Contraline, a clinical-stage biotech developing male contraceptives, raised $92.5 million in Series B funding, CEO Kevin Eisenfrats tells Axios Pro exclusively.
The big picture: The startup hopes growth in direct-to-consumer health care will drive demand when it launches its product commercially.
